Cost-effectiveness analysis
’
SECONDARY
Direct costs of the CBR intervention will be estimated by deriving a monetary value based on actual cost. Cost of illness, as the secondary outcome will be computed based on electronic medical records & self-reported data, and then compared at intermediate line and endline. Cost-effectiveness will be assessed by calculating the incremental cost-effectiveness ratios, which will show the extra cost incurred to produce a unit improvement in symptoms, personal and social function, as well as QALYs gained at the endline. To explore the uncertainty around the estimates, cost-effectiveness acceptability curves will be derived to provide the probability of advantages for the FBC combined CBR at a range of ‘willingness to pay’ threshold levels.